Self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches

Abstract

Recently, European expert recommendations suggested individualized self-monitoring of blood glucose (SMBG) strategies to optimize diabetes management in patients with type 2 diabetes who are treated with glucagon-like peptide-1 (GLP-1)-based approaches. These suggestions include simple and clinically applicable SMBG glucose testing patterns, or schemes. Potential benefits of SMBG in GLP-1-based treatment approaches were seen for several clinical scenarios: early assessment of treatment success or failure, timely modification of treatment, detection of hypoglycemic episodes, assessment of glucose excursions, and support of diabetes management and diabetes education.